Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.6% – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price dropped 7.6% during trading on Monday . The company traded as low as $18.14 and last traded at $18.28. Approximately 27,802 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 840,175 shares. The stock had previously closed at $19.77.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Down 11.1 %

The business’s fifty day moving average price is $24.19 and its 200 day moving average price is $31.16. The company has a market capitalization of $1.01 billion, a P/E ratio of -23.88 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently bought and sold shares of GPCR. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Structure Therapeutics in the 4th quarter worth about $3,091,000. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics in the fourth quarter valued at about $34,000. Woodline Partners LP boosted its position in Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after buying an additional 2,328 shares in the last quarter. Vestal Point Capital LP grew its stake in Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after buying an additional 575,000 shares during the last quarter. Finally, Twinbeech Capital LP increased its holdings in shares of Structure Therapeutics by 34.3% during the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after buying an additional 7,220 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.